Vaxcyte (PCVX) investor relations material

Mission and platform overview

• Focused on engineering high-fidelity vaccines to protect against bacterial diseases globally.

• Utilizes a proprietary cell-free protein synthesis platform (XpressCF) enabling rapid, flexible, and scalable vaccine development.

• Platform allows site-specific conjugation, producing carrier-sparing conjugates that enhance immune response and broaden vaccine coverage.

Pneumococcal conjugate vaccine (PCV) franchise

• VAX-31 is a 31-valent PCV designed to cover ~95% of invasive pneumococcal disease (IPD) in U.S. adults, surpassing current standards.

• VAX-24 is a 24-valent PCV for infants, showing robust immune responses and broader serotype coverage than existing pediatric vaccines.

• Both VAX-31 and VAX-24 leverage carrier-sparing technology to minimize immune suppression and maximize immunogenicity.

• Phase 3 adult trials for VAX-31 (OPUS-1, OPUS-2, OPUS-3) are fully enrolled, with topline data expected in late 2026 and early 2027.

• VAX-31 and VAX-24 have demonstrated safety profiles similar to current PCVs in clinical studies.

Market opportunity and adoption drivers

• The global pneumococcal vaccine market is valued at ~$8B, expected to grow to ~$12B by 2030, driven by expanded adult recommendations.

• Broader serotype and disease coverage is the primary driver of adoption, with healthcare providers favoring higher-coverage PCVs.

• VAX-31 and VAX-24 are positioned to capture significant market share due to their superior coverage and immunogenicity.

• Strategic manufacturing partnerships with Lonza and Thermo Fisher ensure robust supply chain and production capacity.